Interactions of intrathecally administered ziconotide, a selective blocker of neuronal N-type voltage-sensitive calcium channels, with morphine on nociception in rats
- 1 February 2000
- journal article
- Published by Wolters Kluwer Health
- Vol. 84 (2) , 271-81
- https://doi.org/10.1016/s0304-3959(99)00214-6
Abstract
Rathecally (spinally). The present study investigated the acute and chronic (7-day) interactions of intrathecally administered ziconotide and morphine on nociception in several animal models of pain. In the acute study, intrathecal bolus injections of morphine and ziconotide alone produced dose-dependent inhibition of formalin-induced tonic flinch responses and withdrawal responses to paw pressure. The combination of ziconotide and morphine produced an additive inhibition of formalin-induced tonic flinch responses and a significant leftward shift of the morphine dose-response curve in the paw pressure test. After chronic (7-day) intrathecal infusion, ziconotide enhanced morphine analgesia in the formalin test. In contrast, chronic intrathecal morphine infusion produced tolerance to analgesia, but did not affect ziconotide antinociception. Antinociception produced by ziconotide alone was the same as that observed when the compound was co-administered with morphine to morphine-tolerant rats. In the hot-plate and tail immersion tests, chronic intrathecal infusion of morphine lead to rapid tolerance whereas ziconotide produced sustained analgesia with no loss of potency throughout the infusion period. Although ziconotide in combination with morphine produced an apparent synergistic analgesic effects during the initial phase of continuous infusion, it did not prevent morphine tolerance to analgesia. These results demonstrate that (1) acute intrathecal administrations of ziconotide and morphine produce additive or synergistic analgesic effects; (2) chronic intrathecal morphine infusion results in tolerance to analgesia but does not produce cross-tolerance to ziconotide; (3) chronic intrathecal ziconotide administration produces neither tolerance nor cross-tolerance to morphine analgesia; (4) intrathecal ziconotide does not prevent or reverse morphine tolerance....Keywords
This publication has 39 references indexed in Scilit:
- Use of Intrathecal SNX-111, a Novel, N-Type, Voltage-Sensitive, Calcium Channel Blocker, in the Management of Intractable Brachial Plexus Avulsion PainThe Clinical Journal of Pain, 1997
- Direct binding of G-protein βλ complex to voltage-dependent calcium channelsNature, 1997
- Determinants of the G protein-dependent opioid modulation of neuronal calcium channels.Proceedings of the National Academy of Sciences, 1996
- Insights into the development of opioid tolerancePain, 1995
- Calcium channel antagonist peptides define several components of transmitter release in the hippocampusNeuropharmacology, 1994
- The NMDA receptor antagonist eliprodil (SL 82.0715) blocks voltage-operated Ca2+ channels in rat cultured cortical neuronsEuropean Journal of Pharmacology, 1994
- Study of the sensitivity of the diabetes-induced pain model in rats to a range of analgesicsPain, 1994
- Morphine, But Not Inhalation Anesthesia, Blocks Post-injury Facilitation The Role of Preemptive Suppression of Afferent TransmissionAnesthesiology, 1993
- Influence of ω-conotoxin on morphine analgesia and withdrawal syndrome in ratsEuropean Journal of Pharmacology, 1992
- Lack of analgesic effect of opioids on neuropathic and idiopathic forms of painPain, 1988